Grufity logoGrufity logo

NBIX

126.81USD+0.50(+0.40%)Delayed

Neurocrine Biosciences Inc

Market Summary

USD126.81+0.50Delayed
0.40%

NBIX Alerts

NBIX Stock Price

RSI Chart

Valuation

Market Cap

11.1B

Price/Earnings

905.99

Price/Sales

8.52

Price/Cashflow

67.56

MarketCap/EBT

746.83

Price/Sales

Profitability

Operating Margin

98.90%

EBT Margin

1.14%

Return on Equity

0.86%

Return on Assets

0.61%

Fundamentals

Revenue

Revenue (TTM)

1.4B

Revenue Y/Y

31.05%

Revenue Q/Q

2.56%

Earnings

Earnings (TTM)

58.2M

Earnings Y/Y

204.44%

Earnings Q/Q

505.33%

Price Action

52 Week Range

71.88129.29
(Low)(High)

Last 7 days

3.8%

Last 30 days

3.9%

Last 90 days

23.1%

Trailing 12 Months

57.3%

Financial Health

Current Ratio

3.57

Investor Care

Shares Dilution (1Y)

1.34%

Diluted EPS (TTM)

0.58

Peers (Alternatives to Neurocrine Biosciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Neurocrine Biosciences

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue7.1%1,3891,2971,2081,1341,069
Operating Expenses-1,031
  S&GA Expenses4.6%726695655583533
Earnings Before Taxes455.4%821596101157
Net Income377.0%58127190445
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets6.9%2,1432,0062,1452,0732,017
  Current Assets18.3%1,2061,0191,0189731,006
    Cash Equivalents29.9%212163270341311
  Inventory26.3%3729293126
  Net PPE-8.8%6167645951
Liabilities2.8%599582753699671
  Current Liabilities69.8%485286254246226
Shareholder's Equity8.5%1,5451,4231,3911,3741,346
  Retained Earnings12.1%-495.80-564.30-547.40-635.80-628.50
  Additional Paid-In Capital2.7%2,0542,0001,9482,0111,974
Accumulated Depreciation-52----
Shares Outstanding0.5%9696969595
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations22.6%201164129257347
  Share Based Compensation3.8%165159138134120
Cashflow From Investing63.2%-37.80-102.70-224.90-130.20-301.60
Cashflow From Financing1.5%-257.10-261.001827-153.80

Risks

What is the probability of a big loss on NBIX?

76.2%


Probability that Neurocrine Biosciences stock will be more than 20% underwater in next one year

49.6%


Probability that Neurocrine Biosciences stock will be more than 30% underwater in next one year.

17.7%


Probability that Neurocrine Biosciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NBIX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Neurocrine Biosciences was unfortunately bought at previous high price.

Returns

Cumulative Returns on NBIX

32.9%


10-Year Cumulative Returns

13.1%


7-Year Cumulative Returns

11.5%


5-Year Cumulative Returns

2.5%


3-Year Cumulative Returns

What are the long-term rolling returns for NBIX?

FIve years rolling returns for Neurocrine Biosciences.

Which funds bought or sold NBIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
2,505,000
2,505,000
0.03%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.01
1,203,000
16,520,000
0.03%
2022-11-21
FourThought Financial, LLC
ADDED
200
6,000
9,000
-%
2022-11-21
Parallax Volatility Advisers, L.P.
ADDED
18.12
383,000
1,718,000
-%
2022-11-17
M&T Bank Corp
REDUCED
-28.04
784,000
1,078,000
-%
2022-11-17
CENTRAL TRUST Co
NEW
-
45,000
45,000
-%
2022-11-16
Front Row Advisors LLC
NEW
-
7,000
7,000
-%
2022-11-16
TEALWOOD ASSET MANAGEMENT INC
REDUCED
-0.16
121,000
1,505,000
0.81%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
15.93
43,000
205,000
-%
2022-11-16
Neo Ivy Capital Management
NEW
-
19,000
19,000
0.05%

1–10 of 42

Latest Funds Activity

Are funds buying NBIX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own NBIX

Neurocrine Biosciences News

Yahoo Finance

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022.2 days ago

NBIX Fair Value

Recent SEC filings of Neurocrine Biosciences

View All Filings
Date Filed Form Type Document
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Nov 01, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for NBIX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-30
BENEVICH ERIC
SOLD
-6,295,080
125.902
-50,000
Chief Commercial Officer
2022-11-30
BENEVICH ERIC
ACQUIRED
2,073,270
41.4655
50,000
Chief Commercial Officer
2022-11-29
Onyia Jude
SOLD
-284,160
121.905
-2,331
Chief Scientific Officer
2022-11-10
BENEVICH ERIC
ACQUIRED
4,178
41.78
100
Chief Commercial Officer
2022-11-10
BENEVICH ERIC
SOLD
-12,536.2
125.362
-100
Chief Commercial Officer
2022-11-08
Cooke Julie
ACQUIRED
453,232
81.05
5,592
Chief Human Resources Officer
2022-11-08
Lippoldt Darin
SOLD
-635,442
125.038
-5,082
Chief Legal Officer
2022-11-08
Lippoldt Darin
ACQUIRED
219,746
43.24
5,082
Chief Legal Officer
2022-11-08
Cooke Julie
SOLD
-698,949
124.991
-5,592
Chief Human Resources Officer
2022-11-08
BENEVICH ERIC
SOLD
-3,082,320
125.333
-24,593
Chief Commercial Officer

1–10 of 50

Kevin C. Gorman
900
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Income Statement

2022-09-30
Condensed Consolidated Statements of Income and Comprehensive Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Revenues$ 387.9$ 296.0$ 1,076.7$ 821.5
Operating expenses:    
Cost of revenues6.14.215.510.2
Research and development107.792.7345.8240.7
Acquired in-process research and development0.00.00.05.0
Selling, general and administrative186.3154.6569.8426.8
Total operating expenses300.1251.5931.1682.7
Operating income87.844.5145.6138.8
Other income (expense):    
Interest expense(1.2)(6.6)(6.0)(19.2)
Unrealized gain (loss) on equity securities11.1(8.2)23.6(7.5)
Loss on extinguishment of convertible senior notes0.00.0(70.0)0.0
Investment income and other, net0.20.82.83.1
Total other income (expense), net10.1(14.0)(49.6)(23.6)
Income before provision for income taxes97.930.596.0115.2
Provision for income taxes29.48.030.518.3
Net income68.522.565.596.9
Unrealized loss on debt securities available-for-sale, net of tax(1.8)(0.3)(12.3)(1.4)
Comprehensive income$ 66.7$ 22.2$ 53.2$ 95.5
Earnings per share:    
Basic (in USD per share)$ 0.72$ 0.24$ 0.69$ 1.03
Diluted (in USD per share)$ 0.69$ 0.23$ 0.67$ 0.99
Weighted-average shares outstanding:    
Basic (in shares)95.894.795.694.5
Diluted (in shares)99.097.798.397.9
Net product sales    
Revenues:    
Revenues$ 379.3$ 288.8$ 1,036.3$ 786.6
Collaboration revenues    
Revenues:    
Revenues$ 8.6$ 7.2$ 40.4$ 34.9

NBIX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 212.2$ 340.8
Debt securities available-for-sale587.2370.5
Accounts receivable301.2185.5
Inventories37.030.5
Other current assets67.945.5
Total current assets1,205.5972.8
Deferred tax assets319.4315.1
Debt securities available-for-sale362.6560.7
Right-of-use assets89.697.2
Equity securities94.963.7
Property and equipment, net60.958.6
Other assets10.54.4
Total assets2,143.42,072.5
Current liabilities:  
Accounts payable and accrued liabilities297.8225.8
Convertible senior notes169.20.0
Other current liabilities18.120.0
Total current liabilities485.1245.8
Convertible senior notes0.0335.1
Operating lease liabilities96.6105.3
Other long-term liabilities17.112.3
Total liabilities598.8698.5
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding0.00.0
Common stock, $0.001 par value; 220.0 million shares authorized; 96.1 million and 94.9 million shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,054.32,011.4
Accumulated other comprehensive loss(14.0)(1.7)
Accumulated deficit(495.8)(635.8)
Total stockholders’ equity1,544.61,374.0
Total liabilities and stockholders’ equity$ 2,143.4$ 2,072.5